7zlk

Publication Abstract from PubMed

Broadly neutralizing antibodies (bNAbs) have remarkable breadth and potency against most HIV-1 subtypes and are able to prevent HIV-1 infection in animal models. However, bNAbs are extremely difficult to induce by vaccination. Defining the developmental pathways towards neutralization breadth can assist in the design of strategies to elicit protective bNAb responses by vaccination. Here, HIV-1 envelope glycoproteins (Env)-specific IgG+ B cells were isolated at various time points post infection from an HIV-1 infected elite neutralizer to obtain monoclonal antibodies (mAbs). Multiple antibody lineages were isolated targeting distinct epitopes on Env, including the gp120-gp41 interface, CD4-binding site, silent face and V3 region. The mAbs each neutralized a diverse set of HIV-1 strains from different clades indicating that the patient's remarkable serum breadth and potency might have been the result of a polyclonal mixture rather than a single bNAb lineage. High-resolution cryo-electron microscopy structures of the neutralizing mAbs (NAbs) in complex with an Env trimer generated from the same individual revealed that the NAbs used multiple strategies to neutralize the virus; blocking the receptor binding site, binding to HIV-1 Env N-linked glycans, and disassembly of the trimer. These results show that diverse NAbs can complement each other to achieve a broad and potent neutralizing serum response in HIV-1 infected individuals. Hence, the induction of combinations of moderately broad NAbs might be a viable vaccine strategy to protect against a wide range of circulating HIV-1 viruses.

Complementary antibody lineages achieve neutralization breadth in an HIV-1 infected elite neutralizer.,van Schooten J, Schorcht A, Farokhi E, Umotoy JC, Gao H, van den Kerkhof TLGM, Dorning J, Rijkhold Meesters TG, van der Woude P, Burger JA, Bijl T, Ghalaiyini R, Torrents de la Pena A, Turner HL, Labranche CC, Stanfield RL, Sok D, Schuitemaker H, Montefiori DC, Burton DR, Ozorowski G, Seaman MS, Wilson IA, Sanders RW, Ward AB, van Gils MJ PLoS Pathog. 2022 Nov 17;18(11):e1010945. doi: 10.1371/journal.ppat.1010945. , eCollection 2022 Nov. PMID:36395347^[1]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.